These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Listed as ongoing, but also has a completion date 2007-005204-40 A PHASE III STUDY OF VELCADE (BORTEZOMIB) DEXAMETHASONE (VD) VERSUS VELCADE (BORTEZOMIB) THALIDOMIDE DEXAMETHASONE (VTD) AS AN INDUCTION TREATMENT PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATI... 2009-07-02 bad-data
Not reported 2008-003486-58 Pharmacogenomic study to predict survival, best response and toxicity in newly diagnosed myeloma patients who are either 65 years of age or older treated with either a combination of melphalan-prednis... 2016-07-14 due-trials
Ongoing 2009-012359-91 Multicenter Phase II Study of Bendamustine, Velcade (Bortezomib) and Dexamethasone (BVD) in the treatment of elderly patients (> or =65 years) with multiple myeloma in 1st relapse or refractory to 1st... not-yet-due
Not reported 2014-004781-15 Study of Daratumumab in Combination with Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD) in the First Line Treatment of Transplant Eligible Subjects with Newly Diagnosed Multiple Myeloma 2023-09-01 due-trials
Other 2020-004333-20 A phase 2, open label, multisite, single-stage study to evaluate the efficacy of isatuximab plus pomalidomide and dexamethasone (IPd), in patients with AL amyloidosis not in VGPR or better after any p... not-yet-due
Other 2020-005216-21 MInimal residual Disease Adapted Strategy: frontline therapy for patients eligible for autologous stem cell transplantation less than 66 years; a prospective study from the French cooperative group (I... not-yet-due